1. Introduction {#sec1}
===============

The proglucagon-derived peptides (PGDPs) are encoded by a single mammalian gene and include glucagon (GCG), oxyntomodulin, glicentin, and two GCG-like peptides, GLP-1 and GLP-2 [@bib1]. The PGDPs control energy intake, gut motility, mucosal integrity, and the absorption, disposal and storage of ingested energy. The prototype member of the PGDP family, 29 amino acid GCG, is produced in and secreted from islet α-cells, and to a lesser extent, from brainstem neurons [@bib1]. The principal biological role of pancreatic GCG is the maintenance of euglycemia through its control of hepatic glucose production [@bib2], [@bib3], [@bib4].

GCG exerts its metabolic actions through a single GCG receptor (GCGR) [@bib5] highly expressed in hepatocytes but also detected in brain, heart, kidney, gastrointestinal tract, and both white and brown adipose tissue (WAT and BAT, respectively) [@bib6], [@bib7]. Although less extensively studied, GCG exerts direct actions on adipose tissue, encompassing increased blood flow, stimulation of lipolysis, increased glucose uptake and increased oxygen consumption in WAT and BAT [@bib8], [@bib9], [@bib10], [@bib11], [@bib12]. In addition, GCG administration also acutely increases whole body oxygen consumption following administration to animals and humans *in vivo* [@bib13], [@bib14], [@bib15].

Considerable evidence links sustained GCG administration to the reduction of food intake, enhancement of energy expenditure and weight loss in rodent and human studies [@bib16], [@bib17], [@bib18]. Moreover, patients presenting with GCG-producing tumors frequently manifest severe weight loss, through mechanisms that are incompletely understood [@bib19]. Despite several decades of experimentation, the precise processes and cell types contributing to GCG-mediated weight loss remain incompletely understood. Although intracerebroventricular infusion of GCG directly reduces food intake [@bib20] and increases energy expenditure [@bib21], other studies have demonstrated that the GCG-mediated reduction of food intake requires intact hepatic vagal nerve innervation [@bib22] and rats with surgical BAT denervation exhibit diminished metabolic and mitochondrial responses to exogenous glucagon [@bib23].

The clinical development of investigational GCG-containing multi-agonists, including oxyntomodulin and its derivatives [@bib3], [@bib24], [@bib25], for the treatment of diabetes and obesity has rekindled interest in whether and how GCGR signaling results in BAT activation and increased energy expenditure [@bib2], [@bib26], [@bib27]. Several studies invoke an indirect role for GCG on BAT and energy expenditure, acting through enhanced blood flow [@bib28], the sympathetic nervous system (SNS) [@bib29], [@bib30], or fibroblast growth factor (FGF)21 [@bib31], [@bib32]. However, other studies support a direct role for GCG as an activator of oxygen consumption in BAT [@bib14], [@bib33]. Interestingly, GCG infusion in healthy humans subjected to cold exposure increased energy expenditure without evidence for BAT activation as assessed by positron emission tomography scanning [@bib15].

Here we examined the importance of the BAT GCGR for GCG-stimulated energy expenditure in mice and characterized the metabolic phenotype of mice with genetic deletion of the *Gcgr* in BAT using myogenic factor 5 (*Myf5)*-Cre. Using BAT cells and explants *ex vivo*, as well as WT and knockout mice, we demonstrate that GCG acts both directly and indirectly to enhance whole body and BAT oxygen consumption. Nevertheless, the BAT *Gcgr* is physiologically dispensable for GCG-stimulated increase in energy expenditure, and the adaptive metabolic responses to HFD feeding or prolonged cold exposure.

2. Materials and methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

All animal experiments were conducted in accordance with protocols approved by the Toronto Centre for Phenogenomics (TCP) Animal Care Committee. Experiments were performed in group-housed male mice that were maintained on a 12h light/dark cycle at room temperature (RT; 21 °C), 4 °C, or 30 °C and with free access to food and water, except where indicated. Mice were fed either a standard rodent chow diet (RCD; 18% kcal from fat, 2018 Harlan Teklad, Mississauga, ON) or a high-fat diet (HFD; 45% kcal from fat, D12451i, Research Diets, New Brunswick, NJ) for diet-induced obesity analysis. Chronically housed (∼12 weeks) 4 °C group-housed male mice were placed into non-vented microisolator cages (Ancare) with free access to food and water and transferred into environmentally controlled enclosures (Betatech Inc.) at 8--10 weeks of age with an ambient temperature of initially 16 °C. The ambient temperatures within the enclosures were decreased by 2 °C every day until 4 °C ambient temperature was established.

*Gcgr*^BAT−/−^ (BAT-specific *Gcgr* knockout) mice and controls (Cre, Floxed) were generated by crossing hemizygous *Myf5*-Cre mice (007893, The Jackson Laboratory, Bar Harbour, ME) with floxed *Gcgr* mice [@bib34], [@bib35]. Experiments were carried out in all groups of male mice (unless otherwise stated) that were on a C57BL/6J background. However, because the control groups were phenotypically similar with respect to body weight, fat mass, and glucose homeostasis, all control data are presented as a single pooled group (*Myf5*-Cre and *Gcgr*^flox/flox^ mice). Mice were euthanized by CO~2~ inhalation, and tissues were immediately frozen in liquid nitrogen or placed in tissue cassettes for histology analysis. Whole-body *Ucp1*^−/−^ (003124) mice were purchased from The Jackson laboratory. Whole-body *Fgf21*^−/−^ (Fgf^21tm1.1Djm^) mice were provided by Steven A. Kliewer [@bib36].

2.2. Body composition using MRI (magnetic resonance imaging), food intake, indirect calorimetry and *ex vivo* respirometry {#sec2.2}
--------------------------------------------------------------------------------------------------------------------------

Body composition was measured after 32 weeks on RCD or HFD using an Echo MRI nuclear magnetic resonance system (Echo Medical Systems, Houston, TX). Food intake was quantified (over 72 hrs) at 8--10 and 30--32 weeks of age in mice housed individually in cages containing pre-weighed amounts of food. Food intake data in this paper are shown from mice maintained on diet for 30--32 weeks. After 16--18 weeks on RCD or HFD, mice were subjected to indirect calorimetry experiments to measure oxygen consumption, carbon dioxide production, respiratory exchange ratio, activity, and energy expenditure (kcal/h) using a Comprehensive Lab Animal Monitoring System (CLAMS; Columbus Instruments, Columbus OH). For measuring GCG-induced oxygen consumption measurements, mice were fasted for ∼4 h, anesthetized with sodium pentobarbital (60 mg/kg), and placed on a heating pad for 10 mins prior to transferring them into a CLAMS chamber where they were acclimatized for ∼ 8 mins and subsequently given ip injections of vehicle control (acidified PBS) followed by GCG (0.01, 0.1, or 0.5 mg/kg, Sigma, Oakville, ON) or vehicle control followed by GCG (0.5 mg/kg, Sigma), and CL316,243 (1.0 mg kg, Sigma), a selective β-3-adrenergic receptor agonist. For basal *ex vivo* oxygen consumption measurements, fresh tissues were extracted from mice after CO~2~ asphyxiation and immediately placed into warm (37 °C) DMEM (4.5 g/l glucose, L-glutamine, Wisent, St. Bruno, QC) buffer. Tissues were weighed (∼10--20 mg), washed in filtered respiration buffer (PBS, 0.02% fatty acid free BSA, 25 μM glucose, 0.01% (vol/vol) of 100 mM Na pyruvate (Sigma)), minced with scissors, re-suspended in respiration buffer and placed into a Mitocell chamber (MT200A, Strathkelvin Instruments, North Lanarkshire, Scotland) with a Clark electrode (Strathkelvin). For each tissue, measurements were obtained from three separate depots of equivalent size. Recordings were normalized to tissue weight. For stimulated *ex vivo* oxygen consumption measurements, tissues were extracted from littermate mice ∼20--30 minutes after an acute injection of either PBS or GCG (0.5 mg/kg, Sigma).

2.3. Glucose, insulin and lipid tolerance tests {#sec2.3}
-----------------------------------------------

All metabolic tests were performed after a 4--5 h fast. Blood was collected via the tail vein for measuring insulin, GLP-1, GIP, GCG, triglycerides, and FGF21 at indicated time points. For oral and intraperitoneal glucose tolerance tests (oGTT and ipGTT, respectively), D-Glucose (1.5 g/kg; Sigma, Oakville, ON) was administered by oral gavage (oGTT) or ip injection (ipGTT). During insulin tolerance tests (ITT), animals fed a RCD received a single ip injection of 0.7 U/kg BW insulin (Humalog, VL7510, Eli Lily, Scarborough, ON), whereas animals fed a HFD received 1.0 U/kg BW of insulin. When mice were housed at 4 °C, all animals were given a single ip injection of 0.35 U/kg BW of insulin. Blood glucose was measured from the tail vein using a hand-held glucose monitor (Contour, Bayer, Mississauga, ON)) before and 15, 30, 45, 60, 90, and 120 min post-glucose gavage or insulin injection. For lipid tolerance tests (LTT), animals received a 200 μl oral gavage of olive oil (Sigma) at time 0 and blood samples were collected before and 1, 2, and 3 h after gavage.

2.4. Blood collection {#sec2.4}
---------------------

All blood samples (∼50--100 μl) during metabolic tests were collected from tail vein into lithium coated Microvette tubes (Sarstedt, Numbrecht, Germany) and mixed with a 10% volume of TED (5000 kIU/ml Trasylol (Bayer), 32 mM EDTA, and 0.01 mM Diprotin A (Sigma)). Samples were kept on ice and plasma was collected by centrifugation (\>12, 000 rpm at 4 °C for 5 minutes) and stored at - 80 °C.

2.5. Hormone and enzymatic assays {#sec2.5}
---------------------------------

Plasma insulin (Ultrasensitive Mouse Insulin ELISA, Cat\# 80-INSMSU-E01 Alpco Diagnostics, Salem, NH), total GLP-1 (Meso Scale Diagnostics, Cat\# K150JVC-2 Rockville, MD), GIP (Crystal Chem, Cat\# 81517, Elk Grove Village, IL), and GCG (Mercodia, Cat\#10-1281-01) levels were assessed in plasma samples collected before (time 0) and 10 mins post glucose or insulin administration during metabolic tests. Plasma was assayed for non-esterified fatty acids (NEFAs) using the NEFA-HR (2) kit (Wako Diagnostics, Cat\# 999-34691, 995-34791, 991-34891, 993-35191, 276-76491, Mountain View, CA) or triglycerides (TGs) using the Trig-GB kit (Cat\# 05171407, calibrator 11877771216, Roche, Mississauga, ON). For determination of TGs in tissue, frozen iBAT samples were weighed (10--20 mg) and TGs were extracted using a 2:1 chloroform-methanol solution and quantified with Trig-GB kit (Roche). Plasma FGF21 (Millipore, Cat\# EZRMFGF21-26K, Billerica, MA) levels were assayed in fasted (4 h) 8 week old mice fed a RCD.

2.6. RNA isolation and gene expression assays {#sec2.6}
---------------------------------------------

Tissue samples were homogenized in Tri Reagent (Molecular Research Center, Cincinnati, ON) using a TissueLyser II system (Qiagen, Germantown, MD), and total RNA was extracted using the manufacturer\'s protocol. First strand cDNA was synthesized from DNase I-treated total RNA using the SuperScript III and random hexamers (Thermo Fisher Scientific, Markham, ON). Gene expression levels were quantified by real-time PCR using a QuantStudio System and TaqMan Gene Expression Master Mix and Assays (Thermo Fisher Scientific). Primer/probes were purchased from Thermo Fisher Scientific and are listed in [Supplementary Table 1](#appsec1){ref-type="sec"}. qPCR data were analyzed by 2^-ΔΔCt^ method, and expression levels for each gene were normalized to either *Actb* (β-actin) or *Tbp* (TATA-box-binding protein).

2.7. Detection of full-length mouse *Gcgr* mRNA transcripts {#sec2.7}
-----------------------------------------------------------

Full-length (∼1.4 kb) mouse *Gcgr* PCR products were amplified from cDNA using the following primers: forward 5′-CTG CTG CTG CTG CTG TTGG -3′ and reverse 5′-ACC TTG GGA GAC TAC TGGC-3′, separated on an agarose gel, transferred to a nylon membrane, and hybridized overnight with an internal ^32^P-labeled mouse *Gcgr*-specific oligonucleotide probe (5′-AAT GCC ACC ACA ACC TAA GC-3'-). The membrane was washed and then imaged using a Storm 860 Phosphor Screen and Quantity One imaging software (Bio-Rad, Hercules, CA). *Actb* was used as a control for RNA integrity of samples.

2.8. Cell culture: BAT cell line {#sec2.8}
--------------------------------

Immortalized BAT cells were a gift from Dr. Bruce Spiegelman\'s laboratory (Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA) [@bib37]. On Day 0, BAT preadipocyte cells were plated onto collagen coated plates (\<0.006%) containing growth media (DMEM (4.5 g/l glucose, L-glutamine, Wisent, St. Bruno, QC) with 20% FBS (Wisent), 1% Sodium Pyruvate (100 mM, Sigma), \<0.01% HEPES (1M, Wisent), and 1% Penicillin-Strep (Wisent)) and grown until they achieved a healthy mono-layer (∼90--95% confluent). After reaching confluence, on Day 1, growth media was replaced with induction media (DMEM with 10% FBS, 1% Sodium Pyruvate, HEPES and 1% Penicillin-Strep supplemented with 2 μg/ml dexamethasone (Sigma), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX; Sigma), 125 μM indomethacin (Sigma), 10 μg/ml or 1.7 μM insulin (Sigma), and 1 nM T3 (Sigma). After 48 h of induction, on Day 3, media was changed to maintenance media (DMEM (25 mM glucose) with 10% FBS, 1% Sodium Pyruvate, \<0.01% HEPES, and 1% Penicillin-Strep supplemented with 10 μg/ml or 1.7 μM insulin and 1 nM T3, (Sigma), until cells were fully differentiated by Day 7. Fresh media was added to cells as required. All experiments, unless otherwise stated, were performed on fully differentiated cells on Day 7.

To assess the effects of GCG on gene expression or lipolysis, BAT cells were differentiated for 7 days in collagen coated 12-well cell culture dishes (initiated at a density of 40,000 cells per well) in 1 ml of growth media. On Day 7, cells were nutrient-media starved for 3 h in FBS-free DMEM media devoid of all supplements except sodium pyruvate and HEPES. For gene expression assay, BAT cells in each well were treated with media (1 ml) containing either acidified PBS or GCG 100 nM for 1 or 4 h and RNA was isolated by adding 1 ml of Tri-reagent directly into plates and homogenizing cells by repetitive pipetting. For analysis of lipolysis, BAT cells were serum starved for 3 h. Media was then changed to warm (37 °C) filtered Kreb\'s buffer (12 mM Hepes, 121 mM NaCl, 4.9 mM KCL, 1.2 mM MgSO4, 0.33 mM CaCl2, 3% BSA, 3 mM glucose) containing either acidified PBS or GCG (10 nM- 1 μM) for 2 h. Media was then collected into 1.5 ml Eppendorf tubes and frozen at −20 °C. Free glycerol in cell media was measured using a free glycerol assay kit (Cat\# F6428, Sigma), and normalized to protein content (measured using Bradford assay kit (Bio-Rad, Montreal, QC).

2.9. siRNA-induced knockdown of *Gcgr* mRNA in BAT cells {#sec2.9}
--------------------------------------------------------

On Day 0, BAT cells were plated at a density of 80,000 cells per well in 6-well tissue culture dishes containing growth media. Cells were differentiated as described above until Day 4, when differentiated BAT cells were trypsinized, centrifuged and re-suspended in antibiotic-free maintenance media. Differentiated BAT cells were transfected with siRNA duplexes (Universal scrambled negative control (Origene, Rockville, MD) sequence, Cat\# SR30004-CGUUAAUCGCGUAUAAUACGCGUAT) or *Gcgr* (Origene duplex sequence, Cat\# SR415672A-GGAGAAGCCAUGUUAUCUAUGAACT)) diluted in OptiMEM to a final concentration of 50 mM in 1 ml of media using Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific), following the manufacturer\'s protocol. Transfection complexes were added to collagen coated 12-well plates containing 800,000--1,000,000 cells per well suspended in antibiotic-free maintenance media. Maintenance media was replaced every 24 h until Day 7 when cells were harvested for RNA isolation as described above.

2.10. Histological analysis {#sec2.10}
---------------------------

Adipose tissues were fixed in 10% buffered formalin for a minimum of 48 h, and then tissues were transferred into 70% ethanol until processing. Samples were paraffin-embedded, sectioned at 4 μm thickness, slide-mounted, and stained with hematoxylin and eosin. Sections were scanned using the ScanScope CS System (Aperio Tehcnologies, Sausalito, CA) and digital images captured at 100 μM using ScanScope Software (Aperio Technologies).

2.11. Statistics {#sec2.11}
----------------

Data are represented as the mean ± SEM. Statistical significance was determined by one-way ANOVA (post-hoc test Bonferroni), two-way ANOVA (post-hoc test Tukey), paired ([Figure 2](#fig2){ref-type="fig"}D and [Figure S2C](#appsec1){ref-type="sec"}) or unpaired two-tailed Student\'s t-test using GraphPad Prism version 8 Software (San Diego, CA). A p value \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. *Gcgr* mRNA transcripts are expressed at low levels in BAT and GCG directly increases thermogenic gene expression and lipolysis in a BAT cell line {#sec3.1}
-------------------------------------------------------------------------------------------------------------------------------------------------------

*Gcgr* mRNA transcripts were detected by quantitative real time PCR in adipose tissue depots ([Figure 1](#fig1){ref-type="fig"}A) including mesenteric white adipose tissue (mWAT), inguinal (iWAT), epididymal (eWAT), retroperitoneal (rWAT), and interscapular brown adipose tissue (iBAT) ([Figure 1](#fig1){ref-type="fig"}A), corresponding to full length *Gcgr* mRNA ([Figure 1](#fig1){ref-type="fig"}B), albeit at levels 1,000--10,000 fold lower than in liver ([Figure 1](#fig1){ref-type="fig"}A). *Gcgr* mRNA was also detected in a differentiated BAT cell line ([Figure S1A](#appsec1){ref-type="sec"}), associated with induction of *Ucp1* expression ([Figure S1B](#appsec1){ref-type="sec"}). GCG treatment increased levels of *Ucp1*, *Ppargc1a,* and *Cepba* mRNA in BAT cells studied at Day 2 of differentiation ([Figure S1C](#appsec1){ref-type="sec"}) and *Ucp1*, *Ppargc1a, Cidea, Elovl3, Ptgs2*, and *Fgf2*1 mRNA transcripts were increased by GCG on Day 7 ([Figure 1](#fig1){ref-type="fig"}C). Conversely, siRNA-mediated knockdown of *Gcgr* expression reduced levels of *Ucp1*, *Ppargc1a, Elovl3*, *Cebpa, Cidea*, *Lipe,* *Ardb3*, and *Fgf2*1 mRNA transcripts after 2 or 7 days of differentiation ([Figure 1](#fig1){ref-type="fig"}D and [Figure S1D](#appsec1){ref-type="sec"}). CL316,243 was administered to BAT cells in a separate experiment, demonstrating selective induction of mRNA transcripts in response to adrenergic activation ([Figure S1E](#appsec1){ref-type="sec"}). GCG also directly increased lipolysis in a dose-dependent manner in BAT cells ([Figure 1](#fig1){ref-type="fig"}E), through mechanisms requiring the *Gcgr* ([Figure S1F](#appsec1){ref-type="sec"}). Hence, BAT cells express a functional canonical GCGR directly coupled to thermogenic gene expression and lipolysis.Figure 1***Gcgr* is expressed in adipose tissue and GCG administration increases thermogenic genes and lipolysis in BAT cells.** (A) qPCR analysis of *Gcgr* expression (relative to levels in liver) in tissues from 20 week-old WT mice fed a RCD, n = 4. (B) PCR and Southern blot analysis using *Gcgr*-specific internal oligonucleotide probe detected a full length (∼1.4 kb) *Gcgr* mRNA transcript in the liver and adipose tissue; *Actb* PCR of the same samples was used as a control (∼0.3 kb). (C) mRNA transcript levels of thermogenic/lipolytic genes in BAT cells (differentiated for 7 days) 1 h after exposure to GCG (100 nM) expressed relative to levels in cells treated with PBS. The data are representative of 3 independent experiments. (D) Basal mRNA transcript levels in differentiated BAT cells transfected with scrambled control or *Gcgr* siRNA. *Tbp* was used as a housekeeping gene for relative mRNA expression levels. (E) Free glycerol release from differentiated BAT cells in response to a 2 h exposure of increasing doses of GCG or forskolin (Fsk, positive control). mWAT = mesenteric white adipose, iWAT = inguinal WAT, eWAT = epididymal WAT, rWAT = retroperitoneal WAT, iBAT = interscapular brown adipose tissue, N.D. = not detectable. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.Figure 1Figure 2**GCG increases oxygen consumption *in vivo* and *ex vivo,* through UCP1-independent and FGF21-dependent pathways.** (A) Oxygen consumption following an acute injection of PBS or GCG (0.5 mg/kg) in 8--12 week old WT mice fed a RCD and housed at (A) room temperature (RT, ∼21 °C), (B) 4 °C, or (C) 30 °C fed a HFD for 2 weeks, n = 4--6. (D) Oxygen consumption measured in *ex vivo* in iBAT obtained ∼ 20--30 minutes after ip administration of PBS or GCG (0.5 mg/kg) to 12 week old WT mice fed a RCD and housed at RT, n = 6. (E) Oxygen consumption in response to an acute injection of PBS, GCG (0.5 mg/kg), or CL316,243, a selective β-3-adrenergic receptor agonist (1.0 mg/kg), 8--12 week old *Ucp1*^+/+^ and *Ucp1*^−/−^ mice fed a RCD and housed at RT, n = 6--10. (F) Oxygen consumption following an acute administration of PBS or GCG (0.5 mg/kg) in 12--14 week-old *Fgf21*^+/+^ and *Fgf21*^−/−^ mice fed a RCD and housed at RT, n = 10--11. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001. iBAT = interscapular brown adipose tissue.Figure 2

3.2. GCG increases oxygen consumption through UCP1-independent, FGF21-dependent pathways {#sec3.2}
----------------------------------------------------------------------------------------

Considerable evidence demonstrates that acute GCG administration rapidly increases circulating levels of FGF21 in mice and humans [@bib31], [@bib38]. Indeed, acute GCG administration increased oxygen consumption in mice through mechanisms requiring hepatic farnesoid X receptor signaling and FGF21 [@bib32]. We observed that GCG (0.01--0.5 mg/kg) administration rapidly increased oxygen consumption in a dose-dependent manner in RCD-fed WT mice housed at RT ([Figure 2](#fig2){ref-type="fig"}A and [Figure S2A-B](#appsec1){ref-type="sec"}) and in mice fed a HFD ([Figure S2C](#appsec1){ref-type="sec"}). GCG also increased oxygen consumption in WT mice acclimatized to either cold (4 °C, [Figure 2](#fig2){ref-type="fig"}B) or thermoneutral (30 °C, [Figure 2](#fig2){ref-type="fig"}C) temperatures for 2 weeks while fed a HFD. Acute GCG administration to mice also increased oxygen consumption *ex vivo* in both iBAT and liver explants ([Figure 2](#fig2){ref-type="fig"}D and [Figure S2D](#appsec1){ref-type="sec"}, respectively). GCG increased oxygen consumption to similar levels in *Ucp1*^+/+^ vs. *Ucp1*^−/−^ mice, whereas the response to the β-3-adrenergic receptor agonist (CL316,243) was blunted in *Ucp1*^−/−^ mice ([Figure 2](#fig2){ref-type="fig"}E). As circulating FGF21 levels rose rapidly following GCG administration ([Figure S2E](#appsec1){ref-type="sec"}), we assessed the effect of GCG administration in *Fgf21* null mice. In contrast to observations in *Ucp1* null mice, the GCG-induced rise in oxygen consumption was blunted in *Fgf21*^−/−^ mice compared to *Fgf21*^+/+^ control mice ([Figure 2](#fig2){ref-type="fig"}F), consistent with recent findings [@bib32].

3.3. Genetic reduction of iBAT *Gcgr* expression does not regulate body weight and composition {#sec3.3}
----------------------------------------------------------------------------------------------

To determine whether the BAT *Gcgr* contributes to the physiological control of energy homeostasis or the acute response to GCG agonism, we crossed *Gcgr*^flox/flox^ with *Myf5*-Cre mice to generate *Gcgr*^BAT−/−^ mice ([Figure 3](#fig3){ref-type="fig"}A). Consistent with the expression domain of *Myf5*, levels of *Gcgr* mRNA transcripts were lower in rWAT and in BAT from *Gcgr*^BAT−/−^ mice, whereas *Gcgr* expression was not affected in liver, kidney, and jejunum ([Figure 3](#fig3){ref-type="fig"}B, [Figure S3A](#appsec1){ref-type="sec"}). No differences in body weight ([Figure 3](#fig3){ref-type="fig"}C), fat and lean mass ([Figure 3](#fig3){ref-type="fig"}D), adipose tissue or organ weights ([Figure 3](#fig3){ref-type="fig"}E, [Figure S3B](#appsec1){ref-type="sec"}), or adipose tissue histology ([Figure 3](#fig3){ref-type="fig"}F) were detected in RCD-fed or in HFD-fed mice ([Figure 3](#fig3){ref-type="fig"}G--J, [Figure S3C](#appsec1){ref-type="sec"}) housed at RT for 32 weeks. Body temperatures were not different in RCD-fed 8 or 30 week old *Gcgr*^BAT+/+^ vs. *Gcgr*^BAT−/−^ mice after a 16 h overnight fast or after 30 weeks on RCD or HFD ([Figure S3D and S3E](#appsec1){ref-type="sec"}). Basal oxygen consumption was not different in iBAT explants from *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice after 32 weeks on a RCD ([Figure S3F](#appsec1){ref-type="sec"}). Hence, the iBAT *Gcgr* is dispensable for control of body weight in response to RCD or HFD-feeding.Figure 3***Gcgr***^**BAT−/−**^**mice fed RCD or HFD exhibit normal body weight, fat and lean mass, tissue weight, and adipose tissue morphology.** (A) Schematic depicting the generation of *Gcgr*^BAT−/−^ mice (B) qPCR analysis of *Gcgr* mRNA expression in liver and adipose tissues from mice fed a HFD for 32 weeks and housed at RT, n = 4--6. (C) Body weights in *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice (starting at 8--10 weeks of age) fed a RCD and housed at RT, n = 12--19. Fat and lean mass (D), tissue weights relative to body weight (E), and representative H&E stains of adipose tissue sections, the black bars indicating 100 μM. (F) from *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice after 32 weeks of RCD housed at RT, n = 12--19. (G) Body weights of *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice (starting at 8--10 weeks of age) fed a HFD and housed at RT, n = 7--14. Fat and lean mass (H), tissue weights relative to body weight (I), and representative H&E stains of adipose tissue sections, the black bars indicate 100 μM (J) from *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice after 32 weeks of HFD housed at RT, n = 7--14. \*p \< 0.05. *Tbp* was used as a housekeeping gene for relative mRNA expression levels. iWAT = inguinal WAT, eWAT = epididymal WAT, rWAT = retroperitoneal WAT, iBAT = interscapular brown adipose tissue.Figure 3

3.4. Loss of the iBAT Gcgr does not impact food intake, energy expenditure, or glucose homeostasis {#sec3.4}
--------------------------------------------------------------------------------------------------

Food intake, energy expenditure, and the respiratory exchange ratio (RER) were not different in older *Gcgr*^BAT+/+^ vs. *Gcgr*^BAT−/−^ mice maintained on RCD ([Figure 4](#fig4){ref-type="fig"}A--C) or HFD ([Figure 4](#fig4){ref-type="fig"}F--H). Moreover, acute administration of GCG to *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice fed a RCD did not show any differences in oxygen consumption ([Figure 4](#fig4){ref-type="fig"}D). Activity levels were not different ([Figure S4A and S4D](#appsec1){ref-type="sec"}) and the levels of mRNA transcripts for genes regulating thermogenesis or adipose tissue differentiation were similar in adipose tissue depots from RCD- or HFD-fed *Gcgr*^BAT+/+^ vs. *Gcgr*^BAT−/−^ mice ([Figure 4](#fig4){ref-type="fig"}E,I, [Figure S4B,C and S4E,F](#appsec1){ref-type="sec"}). Although small increases in plasma GLP-1 and GCG levels were detected in *Gcgr*^BAT−/−^ fed a RCD ([Figure S5B and S5F](#appsec1){ref-type="sec"}), no differences in glucose or insulin tolerance, plasma levels of insulin, GCG, and GIP, or adipose tissue gene expression were detected in young RCD- or HFD-fed *Gcgr*^BAT+/+^ vs. *Gcgr*^BAT−/−^ mice ([Figure S5A-N](#appsec1){ref-type="sec"}). Similarly, oral and intraperitoneal glucose tolerance ([Figure 5](#fig5){ref-type="fig"}A,B, I and 5J), insulin and lipid tolerance ([Figure 5](#fig5){ref-type="fig"}C,D, K and L), plasma levels of TGs and NEFAs ([Figure 5](#fig5){ref-type="fig"}E, F, M and N), iBAT TGs ([Figure 5](#fig5){ref-type="fig"}G, O), and the relative levels of mRNA transcripts corresponding to genes important for lipid and glucose homeostasis ([Figure 5](#fig5){ref-type="fig"}H, P) were not different in older RCD or HFD-fed *Gcgr*^BAT+/+^ vs. *Gcgr*^BAT−/−^ mice maintained on diets for a longer period of time.Figure 4***Gcgr***^**BAT−/−**^**mice fed a RCD or HFD have normal food intake, energy expenditure, and thermogenic and mitochondrial iBAT mRNA expression profiles.** Food intake (A), basal energy expenditure (B) and RER (C) measured over 36 h in *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice housed at RT and fed RCD for 28 weeks (A) or 16 weeks (B, C). n = 8--19. (D) Oxygen consumption following an acute injection of PBS or GCG (0.5 mg/kg) in 8-week old *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice fed RCD and housed at rt. n = 8--9. (E) iBAT mRNA transcript levels for genes regulating thermogenic, mitochondrial, and differentiation processes in *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice fed RCD for 32 weeks housed at RT, n = 4--6. Food intake (F), basal energy expenditure (G) and RER (H) measured over 36 h in *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice housed at rt and fed RCD for 28 weeks (F) or 16 weeks (G, H). n = 6--12. (I) iBAT mRNA transcript levels for genes regulating thermogenic, mitochondrial and differentiation processes in *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice fed HFD for 32 weeks and housed at RT, n = 4--6. BW = body weight. *Tbp* was used as a housekeeping gene for relative mRNA expression levels. iBAT = interscapular brown adipose tissue.Figure 4Figure 5***Gcgr***^**BAT−/−**^**mice fed RCD or HFD have normal glucose, insulin, and lipid tolerance and glucose and lipid iBAT mRNA expression profiles.** Oral glucose tolerance (A, I), ip glucose tolerance (B, J), insulin tolerance (C, K), plasma triglycerides (TGs) measured at 0, 1, 2, and 3 h post oral lipid gavage during a lipid tolerance test (LTT; D, L), plasma TGs (E, M), plasma non-esterified fatty acids (NEFAs) after an overnight fast and 1 h of refeeding (F, N), iBAT TG levels (G, O), and iBAT mRNA transcript levels of lipid and glucose regulatory genes (H, P) in *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice housed at RT and fed a RCD (A--H) or HFD (I--P) for 22--32 weeks, n = 10--19 for RCD, n = 7--14 for HFD. \*p \< 0.05. *Tbp* was used as a housekeeping gene for relative mRNA expression levels. iBAT = interscapular brown adipose tissue.Figure 5

3.5. Normal metabolic adaptation to cold exposure in *Gcgr*^BAT−/−^ mice {#sec3.5}
------------------------------------------------------------------------

To determine whether the BAT GCGR is important for the metabolic adaptation to chronic cold exposure, we studied HFD-fed *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice maintained at 4 °C for ∼12 weeks. Body weights ([Figure 6](#fig6){ref-type="fig"}A), fat and lean mass and tissue weights ([Figure 6](#fig6){ref-type="fig"}B,C), adipose tissue morphology ([Figure 6](#fig6){ref-type="fig"}D), food intake, energy expenditure, and respiratory exchange ratio (RER) ([Figure 6](#fig6){ref-type="fig"}E--G) were not different between cold-exposed HFD-fed *Gcgr*^BAT+/+^ vs. *Gcgr*^BAT−/−^ mice. Similarly, oral and intraperitoneal glucose tolerance ([Figure 6](#fig6){ref-type="fig"}H,I), insulin and lipid tolerance ([Figure 6](#fig6){ref-type="fig"}J,K), plasma levels of TGs and NEFAs ([Figure 6](#fig6){ref-type="fig"}L, M), iBAT TGs (Figure 6N) and iBAT gene expression profiles (Figure 6O) were also not different between *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice exposed to cold and fed a HFD. Furthermore, body temperature ([Figure S6A](#appsec1){ref-type="sec"}), tissue weights ([Figure S6B](#appsec1){ref-type="sec"}), basal iBAT oxygen consumption ([Figure S6C](#appsec1){ref-type="sec"}), and activity levels ([Figure S6D](#appsec1){ref-type="sec"}) were similar in HFD-fed *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice after 10--12 weeks of cold exposure. Collectively, these results demonstrate that BAT GCGR is dispensable for the regulation of energy (food intake, energy expenditure, body composition), glucose and lipid metabolism, both in young and old mice, and in mice fed a RCD, or a HFD, and studied at different ambient temperatures.Figure 6***Gcgr***^**BAT−/−**^**mice fed a HFD and housed at 4 °C exhibit normal glucose, insulin, and lipid tolerance and energy expenditure**. Body weights (A), fat and lean mass (B), tissue weights (C), representative H&E stains of adipose tissue sections, the black bars indicated 100 μM (D), food intake (E), basal energy expenditure measured at RT (F), basal RER (G), oral (H) and ip (I) glucose tolerance, insulin tolerance (J), plasma triglycerides (TGs) measured at 0, 1, 2, and 3 h post oral lipid gavage during a lipid tolerance test (LTT; K), plasma TGs (L), plasma non-esterified fatty acids (NEFAs) after an overnight fast and 1 h of refeeding (M), iBAT TG levels (N), and iBAT mRNA transcript levels of thermogenic, mitochondrial and lipid/glucose regulatory genes, (O) in *Gcgr*^BAT+/+^ and *Gcgr*^BAT−/−^ mice housed at 4 °C and fed a HFD for 2 wks (H), 4 wks (J), 6 wks (I), 8 wks (K), 10 wks (E, F, G), 11 wks (L, M) or 12 wks (A-D, N, O). n = 4--8. \*p \< 0.05. All mRNA transcript levels were measured relative to levels of the housekeeping gene *Tbp*. iWAT = inguinal WAT, eWAT = epididymal WAT, rWAT = retroperitoneal WAT, iBAT = interscapular brown adipose tissue.Figure 6

4. Discussion {#sec4}
=============

Considerable experimentation links acute GCG administration to increased core body temperature [@bib39], BAT blood flow [@bib28], BAT mass, and thermogenic activity [@bib17], [@bib23], as well as enhanced energy expenditure in rodents and humans [@bib13], [@bib40]. Moreover, several studies have demonstrated direct actions of GCG on BAT [@bib11], [@bib41], raising the possibility that GCGR activity contributes to the endogenous control of whole body energy expenditure. Herein, we refine the mechanistic importance of these findings by using mouse genetics to test the relative importance of the murine BAT GCGR for the acute response to GCG administration, and the long term physiological control of energy homeostasis.

Pharmacological GCG agonism produces weight loss through reduction in food intake and via potentiation of thermogenic mechanisms to increase energy expenditure [@bib3], [@bib4]. Indeed, GCG-containing peptide multi-agonists require a functional GCGR to reduce fat mass and generate weight loss in HFD-fed mice, actions reflecting a combination of reduced food intake and enhanced energy expenditure [@bib42]. Similarly, the weight loss observed with the GCG-GLP-1 co-agonist MEDI0382 in preclinical studies was partially attributed to GCGR-dependent induction of energy expenditure [@bib43]. Identification of the key tissues essential for the GCGR-dependent control of energy expenditure remains incomplete, and the available evidence supports a role for multiple organs, including liver and adipose tissue, in transducing GCGR-stimulated signals linked to enhanced oxygen consumption [@bib3], [@bib32]. Although GCG administration increased *Ucp1* expression in BAT and increased *Fgf2*1 mRNA transcripts in murine liver [@bib12], [@bib44], our current data demonstrate that *Ucp1* is not required for acute GCG induction of oxygen consumption.

Consistent with recent independent studies, we confirm that the GCG-induced increase in oxygen consumption is only partially blunted in *Fgf21*^−/−^ mice [@bib32], implicating additional GCGR-dependent mechanisms contributing to the acute GCG-dependent enhancement of energy expenditure. Notably, glucagon administration may increase oxygen consumption in the liver, adipose tissue, and possibly other tissues [@bib31]. Whether these actions, partially independent of FGF21, reflect additional recruitment of downstream mediators, or direct signaling from the GCGR to mitochondrial pathways, requires further exploration.

Our analysis of relative *Gcgr* gene expression across a range of tissues revealed that levels of adipose tissue *Gcgr* mRNA transcripts were not abundant, being several orders of magnitude lower in WAT compared to liver, and even lower in BAT. Nevertheless, acute administration of GCG to mice increased oxygen consumption not only in the liver, but also in BAT. Furthermore, our studies with BAT cells *in vitro* demonstrated that enhanced or reduced *Gcgr* expression was associated with the regulation of lipolysis and the expression of genes linked to the control of energy expenditure. Hence, to identify a role for the BAT *Gcgr* in the pharmacological response to acute *Gcgr* administration *in vivo*, we generated and characterized *Gcgr*^BAT−/−^ mice. Unexpectedly, GCG administration robustly induced oxygen consumption to a similar extent in *Gcgr*^BAT+/+^ vs. *Gcgr*^BAT−/−^ mice. Taken together, these results suggest that the murine BAT GCGR is not an important molecular target for the acute pharmacological actions of GCG administration, findings consistent with the lack of increased neck temperature or BAT glucose uptake in healthy male humans following transient GCG infusion [@bib15].

The generation of mice with a marked reduction of BAT *Gcgr* expression provided an opportunity to determine the physiological importance of the GCGR within the cellular domains targeted by *Myf5*-Cre. Notably, the BAT *Gcgr* is not required for control of body weight, adiposity, core temperature, or energy expenditure, either when housed at RT or 4 °C. Moreover, we detected no differences in these parameters in mice maintained on a RCD or HFD. Furthermore, glucose homeostasis and lipid tolerance was not different in *Gcgr*^BAT+/+^ vs. *Gcgr*^BAT−/−^ mice, whether maintained in the cold, or at RT and studied after exposure to RCD or HFD conditions. Hence, the totality of the data is consistent with the very low level of BAT *Gcgr* expression and reveals that the BAT *Gcgr* is dispensable for metabolic adaptation to energy excess or a cold environment.

5. Limitations {#sec5}
==============

Our studies have several limitations. First, we focused on acute pharmacological GCG administration in young male C57Bl/6 mice and cannot rule out a role for the BAT GCGR in transduction of a component of weight loss observed with more sustained GCGR agonism in a wider range of mice and conditions [@bib32]. Second, we did not study mice with experimental diabetes; hence, our conclusions are limited to mice analyzed under RCD and HFD feeding. Third, we did not examine the actions of GCG-containing multi-agonists, and it is possible that BAT GCGR activation may be more important when GCG is combined with one or more peptides with complementary metabolic activity. Nevertheless, within the context of these limitations, the results of our studies are quite conclusive and suggest that the BAT GCGR is dispensable for the acute metabolic response to GCG administration and the physiological control of energy homeostasis.
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Appendix A. Supplementary data {#appsec1}
==============================

The following are the Supplementary data to this article:Multimedia component 1Multimedia component 1Multimedia component 2**Figure S1. *Gcgr* and *Ucp1* mRNA expression levels during BAT cell differentiation.***Gcgr* (A) and *Ucp1* (B) mRNA expression at days of differentiation in BAT cells. (C) mRNA expression levels of genes in BAT Cells (Day 2) after 4 h of treatment with PBS or GCG (100 nM). (D) mRNA expression levels of genes from BAT cells transfected with scrambled or siRNA *Gcgr* on Day 2 of differentiation. (E) mRNA expression in BAT cells (Day 7) after 1 h of treatment with CL316,243 (β-3-adrenergic agonist). (F) Free glycerol release from differentiated BAT cells that were transfected with scrambled or *Gcgr* siRNA and treated with either PBS or GCG (500 nM) for 2 h. All gene expression data are expressed relative to the mRNA levels for the housekeeping genes *Actb* (A and B) and *Tbp* (C-E). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. **Figure S2. GCG increases oxygen consumption in WT mice housed at room temperature for 2 weeks.** (A) Oxygen consumption in response to ip injection of GCG (0.5mg/kg) and (B) Oxygen consumption in response to i.p. injection of different doses of GCG (0.01, 0.1 and 0.5 mg/kg), relative to PBS baseline, in 12 week old WT mice fed a RCD for 2 weeks, n=4. (C) Oxygen consumption in mice fed HFD given 0.5 mg/kg GCG (n=3) compared to a mouse administered PBS. (D) Oxygen consumption in liver explants from 12 week old WT mice fed a RCD and treated with either PBS or GCG (0.5 mg/kg) at 12 weeks of age n=4. (E) Plasma FGF21 levels (% change from fasted levels) from 8 week old GCG (0.5 mg/kg)-injected WT mice on RCD, n=4-5. \*p\<0.05, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. **Figure S3. *Gcgr* expression, tissue weights, body temperature, and basal iBAT oxygen consumption in *Gcgr***^**BAT+/+**^**and *Gcgr***^**BAT-/-**^**mice fed a RCD or HFD and housed at RT.** (A) *Gcgr* mRNA expression in tissues from 16 week old female mice, n=3-6. *Actb* was used as a housekeeping gene for relative mRNA expression levels. Tissue weights from *Gcgr*^BAT+/+^ and *Gcgr*^BAT-/-^ mice fed a RCD (B) or HFD (C). Body temperature after an overnight fast in 8 week old *Gcgr*^BAT+/+^ and *Gcgr*^BAT-/-^ mice fed a RCD (D; n=13-18) or 30 week old mice fed a HFD (E; n=6-13). Oxygen consumption measured *ex vivo* in iBAT from *Gcgr*^BAT+/+^ and *Gcgr*^BAT-/-^ mice fed RCD and housed at RT for 32 weeks (F; n=8-11). \*p\<0.05. iBAT= interscapular brown adipose tissue. **Figure S4. Activity levels and gene expression profiles in rWAT and eWAT from *Gcgr***^**BAT+/+**^**and *Gcgr***^**BAT-/-**^**mice.** Basal activity measured at RT in *Gcgr*^BAT+/+^ and *Gcgr*^BAT-/-^ mice fed a RCD (A) or a HFD (D) for 16 weeks, n=4-6. Levels of mRNA transcripts for thermogenic genes in rWAT (B, E) and eWAT (C, F) tissues from *Gcgr*^BAT+/+^ and *Gcgr*^BAT-/-^ mice fed a RCD (B, C) or a HFD (E, F) for 32 weeks, n=4-6. All mRNA expression levels were measured relative to the housekeeping gene *Tbp*. rWAT=retroperitoneal white adipose tissue, eWAT= epididymal white adipose tissue. \*p\<0.05. **Figure S5. Metabolic measurements in young *Gcgr***^**BAT+/+**^**and *Gcgr***^**BAT-/-**^**mice fed a RCD or HFD and housed at RT.** Blood glucose levels measured during an oral glucose tolerance test (oGTT; A, H) and plasma insulin, GIP and GLP-1 levels at 0 and 10 minutes post oral glucose gavage (B, I) in *Gcgr*^BAT+/+^ and *Gcgr*^BAT-/-^ mice after 2 weeks on RCD (A, B) or HFD (H, I). Blood glucose levels measured during an ip glucose tolerance test (ipGTT; C, J) and plasma insulin levels (D, K) measured at 0 and 15 minutes after ip glucose injection in *Gcgr*^BAT+/+^ and *Gcgr*^BAT-/-^ mice after 6 weeks on RCD (C, D) or HFD (J, K). Blood glucose levels measured during an insulin tolerance test (ITT; E, L) and plasma GCG measured in mice at 0 and 30 minutes post insulin injection (F, M) in *Gcgr*^BAT+/+^ and *Gcgr*^BAT-/-^ mice after 4 weeks on RCD (E, F) or HFD (L, M). qPCR analysis of mRNA levels for genes expressed in rWAT and eWAT tissue from *Gcgr*^BAT+/+^ and *Gcgr*^BAT-/-^ mice after 32 weeks on RCD (G) or HFD (N). All mRNA levels were normalized relative to the housekeeping gene *Tbp*. For A-N, n=13-19 for RCD and n=8-12 for HFD. rWAT=retroperitoneal white adipose tissue, eWAT= epididymal white adipose tissue. \* p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. **Figure S6. Body temperature, tissue weights, basal iBAT oxygen consumption and basal activity in *Gcgr***^**BAT+/+**^**and *Gcgr***^**BAT-/-**^**mice fed HFD and housed at 4°C for 12 weeks.** Body temperature after an overnight fast (∼ 16 hrs) (A), tissue weights (B), basal iBAT oxygen consumption (C), and basal activity levels measured at RT (D) in *Gcgr*^BAT+/+^ and *Gcgr*^BAT-/-^ mice fed a HFD and housed at 4°C for 10 weeks. n=5-7. iBAT= interscapular brown adipose tissue. **Supplementary Table 1** List of primers used for qPCR.Multimedia component 2
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